Henry Schein Reports Strong Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Should l Buy HSIC?
Henry Schein Inc's stock rose by 6.63% as it reached a 52-week high, reflecting strong investor confidence following the company's impressive Q4 2025 financial results.
In Q4 2025, Henry Schein reported total net sales of $3.4 billion, a 7.7% increase year-over-year, with a GAAP diluted EPS of $0.85, up 14.9% from the previous year. The company also announced a stock repurchase program totaling $850 million, demonstrating confidence in its stock value and commitment to shareholder returns. This strong performance and optimistic future outlook, projecting non-GAAP diluted EPS between $5.23 and $5.37 for 2026, have significantly bolstered investor sentiment.
The robust financial results and strategic initiatives position Henry Schein favorably in the healthcare market, likely attracting further investor interest and enhancing its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSIC
Wall Street analysts forecast HSIC stock price to fall
10 Analyst Rating
5 Buy
3 Hold
2 Sell
Moderate Buy
Current: 79.150
Low
58.00
Averages
76.78
High
90.00
Current: 79.150
Low
58.00
Averages
76.78
High
90.00
About HSIC
Henry Schein, Inc. is a solutions company for healthcare professionals. Its segments consist of Global Distribution and Value-Added services, Global Specialty Services, and Global Technology. Global Distribution and Value-Added Services include the distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under its own brand, a portfolio of consumable merchandise. The Global Specialty Products includes the manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other healthcare-related products and services. Global Technology includes the development and distribution of practice management software, e-services, and other products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Henry Schein to Release Q1 2026 Financial Results
- Earnings Release Schedule: Henry Schein will announce its Q1 2026 financial results before the market opens on May 5, 2026, demonstrating the company's commitment to transparency and investor communication.
- Live Webcast Conference: A conference call will take place at 8:00 a.m. Eastern Time on the same day, featuring CEO Frederick M. Lowery and CFO Ronald N. South, which enhances investor confidence in the company's future prospects.
- Global Business Overview: Operating in 34 countries, Henry Schein reported sales of $13.2 billion in 2025, with a compound annual growth rate of approximately 11%, reflecting its strong performance in the healthcare solutions market.
- Diverse Products and Services: The company offers over 300 solutions to more than 1 million customers globally, showcasing its extensive influence and market leadership in the healthcare industry.
See More
Henry Schein Board to Reduce Size to 10 Members
- Board Size Adjustment: Henry Schein (HSIC) announced plans to reduce its board from 15 to 10 members, effective after the May 21 stockholder meeting, aiming to enhance decision-making efficiency and optimize corporate governance.
- Executive Retirement and Succession: Chairman Stanley Bergman, who has served for over 30 years, will retire and be named chairman emeritus, reflecting the company's recognition of his long-term contributions while paving the way for new leadership.
- Multiple Directors Not Seeking Reelection: In addition to Bergman, board members Joseph Herring, Robert Hombach, Scott Serota, and Bradley Sheares will not seek reelection, which may influence the company's strategic direction moving forward.
- Leadership Transition Period: Amidst this leadership change, Henry Schein has set a 2026 EPS growth target of 5%-8%, indicating the company's commitment to sustainable growth while maintaining operational stability.
See More
Henry Schein Board Restructuring and Chairman Emeritus Appointment
- Board Size Reduction: Henry Schein announced plans to reduce its Board of Directors from 15 to 10 members following the 2026 Annual Meeting, a move aimed at enhancing decision-making efficiency and optimizing governance structure, which is expected to strengthen the company's competitive position in healthcare solutions.
- Chairman Emeritus Appointment: Stanley M. Bergman will retire after 44 years on the Board and be named Chairman Emeritus, recognizing his significant contributions while ensuring he continues to provide strategic guidance, thereby enhancing leadership stability within the company.
- New Director Nominations: The slate of directors nominated for the 2026 Annual Meeting includes nine members such as Mohamad Ali, with the Board believing this new lineup will foster effective dialogue and debate, thus driving the achievement of the company's strategic objectives.
- Acknowledgment of Retiring Directors: The company expressed gratitude to retiring directors like Joseph L. Herring, emphasizing their expertise and guidance as instrumental to Henry Schein's development, reflecting the company's commitment to valuing its talent and leadership.
See More
Veteran Value Fund Manager Highlights Williams, Henry Schein, and 3 Other Discount Stocks
Market Performance: Wall Street has had a challenging start to the year, with mixed results across different stock categories.
Value vs. Growth Stocks: Investors in value stocks are performing better, as evidenced by the Vanguard Value ETF's 3.3% increase in 2026, contrasting with a 9.5% decline in the Vanguard Growth ETF.
See More
Henry Schein Recognized as One of the 2026 World's Most Ethical Companies for 15th Consecutive Year
- Ethical Recognition: Henry Schein has been named one of the 2026 World's Most Ethical Companies by Ethisphere for the 15th consecutive year, highlighting its excellence in business ethics, compliance, and governance, which reinforces its leadership position in the healthcare solutions industry.
- Corporate Citizenship Commitment: Celebrating 25 years of its global corporate citizenship program, Henry Schein has provided nearly $18 million in cash and products to global charity partners, embodying the company's philosophy of 'doing well by doing good' to enhance access to healthcare.
- Risk Management Enhancement: The company has strengthened its Third-Party Risk Management program by issuing Global Principles & Policy on Third Party Intermediaries, ensuring high standards of ethics and compliance in its relationships with suppliers and partners, thereby mitigating potential business risks.
- Ethical Culture Promotion: Henry Schein has introduced a 'Leading with Integrity: A Toolkit for Ethical Leadership' for managers globally, aiming to enhance employees' ethical awareness and decision-making capabilities, which is crucial for the company's long-term success in ethics and compliance.
See More
Henry Schein Reports Strong Q4 Earnings Amid Industry Trends
- Henry Schein's Strong Performance: Henry Schein reported Q4 revenues of $3.44 billion, a 7.7% year-over-year increase, exceeding analyst expectations by 2.8%, reflecting robust growth momentum in global healthcare product distribution, particularly in equipment and technology sectors.
- Envista's Outstanding Results: Envista achieved revenues of $750.6 million, up 15% year-over-year, outperforming analyst expectations by 10.6%, marking it as the fastest-growing company among peers, although its stock has traded sideways post-report, indicating market expectations were already priced in.
- Dentsply Sirona's Challenges: Dentsply Sirona reported revenues of $961 million, a 6.2% year-over-year increase, surpassing expectations by 4.2%, but its full-year revenue and EPS guidance significantly missed analyst forecasts, leading to an 8.5% decline in stock price.
- Align Technology's Steady Growth: Align Technology's Q4 revenues reached $1.05 billion, up 5.3% year-over-year, beating analyst expectations by 1.2%, although it had the weakest performance among peers, yet its stock rose 1.6%, reflecting market confidence in its long-term potential.
See More
Henry Schein to Release Q1 2026 Financial Results
- Earnings Release Schedule: Henry Schein will announce its Q1 2026 financial results before the market opens on May 5, 2026, demonstrating the company's commitment to transparency and investor communication.
- Live Webcast Conference: A conference call will take place at 8:00 a.m. Eastern Time on the same day, featuring CEO Frederick M. Lowery and CFO Ronald N. South, which enhances investor confidence in the company's future prospects.
- Global Business Overview: Operating in 34 countries, Henry Schein reported sales of $13.2 billion in 2025, with a compound annual growth rate of approximately 11%, reflecting its strong performance in the healthcare solutions market.
- Diverse Products and Services: The company offers over 300 solutions to more than 1 million customers globally, showcasing its extensive influence and market leadership in the healthcare industry.
See More
Henry Schein Board to Reduce Size to 10 Members
- Board Size Adjustment: Henry Schein (HSIC) announced plans to reduce its board from 15 to 10 members, effective after the May 21 stockholder meeting, aiming to enhance decision-making efficiency and optimize corporate governance.
- Executive Retirement and Succession: Chairman Stanley Bergman, who has served for over 30 years, will retire and be named chairman emeritus, reflecting the company's recognition of his long-term contributions while paving the way for new leadership.
- Multiple Directors Not Seeking Reelection: In addition to Bergman, board members Joseph Herring, Robert Hombach, Scott Serota, and Bradley Sheares will not seek reelection, which may influence the company's strategic direction moving forward.
- Leadership Transition Period: Amidst this leadership change, Henry Schein has set a 2026 EPS growth target of 5%-8%, indicating the company's commitment to sustainable growth while maintaining operational stability.
See More
Henry Schein Board Restructuring and Chairman Emeritus Appointment
- Board Size Reduction: Henry Schein announced plans to reduce its Board of Directors from 15 to 10 members following the 2026 Annual Meeting, a move aimed at enhancing decision-making efficiency and optimizing governance structure, which is expected to strengthen the company's competitive position in healthcare solutions.
- Chairman Emeritus Appointment: Stanley M. Bergman will retire after 44 years on the Board and be named Chairman Emeritus, recognizing his significant contributions while ensuring he continues to provide strategic guidance, thereby enhancing leadership stability within the company.
- New Director Nominations: The slate of directors nominated for the 2026 Annual Meeting includes nine members such as Mohamad Ali, with the Board believing this new lineup will foster effective dialogue and debate, thus driving the achievement of the company's strategic objectives.
- Acknowledgment of Retiring Directors: The company expressed gratitude to retiring directors like Joseph L. Herring, emphasizing their expertise and guidance as instrumental to Henry Schein's development, reflecting the company's commitment to valuing its talent and leadership.
See More
Veteran Value Fund Manager Highlights Williams, Henry Schein, and 3 Other Discount Stocks
Market Performance: Wall Street has had a challenging start to the year, with mixed results across different stock categories.
Value vs. Growth Stocks: Investors in value stocks are performing better, as evidenced by the Vanguard Value ETF's 3.3% increase in 2026, contrasting with a 9.5% decline in the Vanguard Growth ETF.
See More
Henry Schein Recognized as One of the 2026 World's Most Ethical Companies for 15th Consecutive Year
- Ethical Recognition: Henry Schein has been named one of the 2026 World's Most Ethical Companies by Ethisphere for the 15th consecutive year, highlighting its excellence in business ethics, compliance, and governance, which reinforces its leadership position in the healthcare solutions industry.
- Corporate Citizenship Commitment: Celebrating 25 years of its global corporate citizenship program, Henry Schein has provided nearly $18 million in cash and products to global charity partners, embodying the company's philosophy of 'doing well by doing good' to enhance access to healthcare.
- Risk Management Enhancement: The company has strengthened its Third-Party Risk Management program by issuing Global Principles & Policy on Third Party Intermediaries, ensuring high standards of ethics and compliance in its relationships with suppliers and partners, thereby mitigating potential business risks.
- Ethical Culture Promotion: Henry Schein has introduced a 'Leading with Integrity: A Toolkit for Ethical Leadership' for managers globally, aiming to enhance employees' ethical awareness and decision-making capabilities, which is crucial for the company's long-term success in ethics and compliance.
See More
Henry Schein Reports Strong Q4 Earnings Amid Industry Trends
- Henry Schein's Strong Performance: Henry Schein reported Q4 revenues of $3.44 billion, a 7.7% year-over-year increase, exceeding analyst expectations by 2.8%, reflecting robust growth momentum in global healthcare product distribution, particularly in equipment and technology sectors.
- Envista's Outstanding Results: Envista achieved revenues of $750.6 million, up 15% year-over-year, outperforming analyst expectations by 10.6%, marking it as the fastest-growing company among peers, although its stock has traded sideways post-report, indicating market expectations were already priced in.
- Dentsply Sirona's Challenges: Dentsply Sirona reported revenues of $961 million, a 6.2% year-over-year increase, surpassing expectations by 4.2%, but its full-year revenue and EPS guidance significantly missed analyst forecasts, leading to an 8.5% decline in stock price.
- Align Technology's Steady Growth: Align Technology's Q4 revenues reached $1.05 billion, up 5.3% year-over-year, beating analyst expectations by 1.2%, although it had the weakest performance among peers, yet its stock rose 1.6%, reflecting market confidence in its long-term potential.
See More
